News
09-24-2018, 01:28 AM
Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.
More... (https://www.news-medical.net/news/20180924/ADCETRIS-drug-receives-approval-in-Japan-as-frontline-treatment-option-for-Hodgkin-lymphoma.aspx)
More... (https://www.news-medical.net/news/20180924/ADCETRIS-drug-receives-approval-in-Japan-as-frontline-treatment-option-for-Hodgkin-lymphoma.aspx)